StockData

Bicycle Therapeutics vs Foghorn Therapeutics

BCYC and FHTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BCYC and FHTX compare

Bicycle Therapeutics is the larger company, worth 2.1 times as much as Foghorn Therapeutics ($224M against $109M).

Bicycle Therapeutics grew revenue faster over the last twelve months (195% versus 52.0% for Foghorn Therapeutics).

Bicycle Therapeutics keeps more of each dollar of sales as profit, with a net margin of −170% compared with −176% at Foghorn Therapeutics.

Bicycle Therapeutics scores higher on the StockData Score (11 against 9 for Foghorn Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBCYCFHTX
Size and price
Market cap$224M$109M
Share price$3.20$1.83
Change, 1 year−50.6%−61.0%
Change, 5 years−94.1%−86.6%
Beta (5Y)2.102.82
Employees288106
StockData Score
Total score11 (better)9
Valuation score3 (better)1
Growth score22
Performance score2 (better)1
Health score45 (better)
Dividend score00
Valuation
P/S2.7× (better)3.0×
P/B0.4×–
FCF yield−78.9%−77.6% (better)
Fair value$16.12–
Margin of safety80.1%–
Growth
Revenue growth (TTM)195% (better)52.0%
Revenue growth, 5Y average47.5%135% (better)
Profitability
Operating margin−189% (better)−198%
Net margin−170% (better)−176%
FCF margin−212% (better)−229%
Return on equity−25.2%–
Return on invested capital−4543%–
Financial health
Debt / equity0.00–
Interest coverage−815.6×–
Current ratio12.09 (better)3.36
Altman Z-score−0.08 (better)−4.61
Piotroski F-score22
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Shareholder yield0.00%0.00%
Ownership
Held by institutions53.4%75.6%
Held by insiders21.3%36.3%
Insider net buying, 12 months−$523K–
Short interest, % of float–6.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.